Latest News on INCY

Financial News Based On Company


Advertisement
Advertisement

Align Technology appoints Paul J Clancy, Ian Bell to its board

https://medicalbuyer.co.in/align-technology-appoints-paul-j-clancy-ian-bell-to-its-board/
Align Technology, Inc. has announced the appointment of Paul J. Clancy and Ian Bell to its Board of Directors. Clancy, a biopharmaceutical executive, joined immediately, while Bell, Senior Vice President and COO of Alcon Inc., will join on December 10, 2026. These appointments aim to leverage their extensive global healthcare, financial, innovation, and operational leadership experience to support Align's strategic execution and long-term growth.

Align Technology appoints two directors to board By Investing.com

https://ca.investing.com/news/stock-market-news/align-technology-appoints-two-directors-to-board-93CH-4967824
Align Technology Inc. (NASDAQ:ALGN) has appointed Paul J. Clancy and Ian Bell to its Board of Directors. Clancy, with over 30 years of experience in biotech and pharma, joins immediately, while Bell, a current Senior Vice President and COO at Alcon Inc., will join on December 10, 2026. These appointments will temporarily increase the board to 13 directors before C. Raymond Larkin, Jr. retires at the end of 2026, reducing the total to 12.

Paul J. Clancy and Ian Bell to Join Align Technology Board of Directors

https://www.businesswire.com/news/home/20261118992581/en/Paul-J.-Clancy-and-Ian-Bell-to-Join-Align-Technology-Board-of-Directors
Align Technology, Inc. has announced the appointment of Paul J. Clancy and Ian Bell to its Board of Directors. Paul J. Clancy, a former CFO of Alexion Pharmaceuticals and Biogen, joins immediately, bringing over 30 years of strategic, financial, and operational leadership experience. Ian Bell, Senior Vice President and Chief Operating Officer of Alcon Inc., will join on December 10, 2026, contributing broad experience across commercial, manufacturing, quality, and regulatory operations.

FDA Accepts Karyopharm Therapeutics' Selinexor Plus Ruxolitinib Application for Myelofibrosis

https://oncodaily.com/hematology/karyopharm-therapeutics-634951
The U.S. Food and Drug Administration (FDA) has accepted Karyopharm Therapeutics' supplemental New Drug Application for selinexor plus ruxolitinib to treat myelofibrosis. This submission is based on data from the Phase 3 SENTRY trial, which evaluated the combination's impact on spleen volume and symptom burden in patients who had not previously received a JAK inhibitor. If approved, this regimen could become the first combination therapy for myelofibrosis, addressing a significant unmet need for patients with this rare blood cancer.

Jefferies reiterates Hold on Incyte stock with $115 price target By Investing.com

https://in.investing.com/news/stock-market-news/jefferies-reiterates-hold-on-incyte-stock-with-115-price-target-93CH-5709617
Jefferies has reiterated a "Hold" rating on Incyte Corp. (NASDAQ: INCY) with a price target of $115.00, despite the stock currently trading higher. The firm highlighted Incyte's strategic focus on developing its business beyond Jakafi, identifying myeloproliferative neoplasms and gastrointestinal cancers as key growth areas, with anticipated business development activity in 2027.
Advertisement

Incyte says EU approves oral treatment for chronic skin disease

https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/incyte-says-eu-approves-oral-treatment-for-chronic-skin-disease/135907602
The European Commission has approved Incyte's oral therapy, Povofortay (povorcitinib), for adults with moderate-to-severe hidradenitis suppurativa. This approval marks a potential new growth area for Incyte, aiming to diversify its portfolio beyond its blood cancer drug Jakafi. Povofortay works by blocking JAK1 and showed significant symptom improvement in late-stage studies.

Acrivon Therapeutics Q3 Results: Loss narrows to $(0.42) per share

https://scanx.trade/stock-market-news/companies/acrivon-therapeutics-q3-results-loss-narrows-0-42-per-share/56420062
Acrivon Therapeutics reported a Q3 loss of $(0.42) per share, which beat the analyst consensus estimate of $(0.46) by 8.7%. This result signifies a 10.64% improvement in losses compared to the previous year's $(0.47) per share. The narrowing deficit suggests enhanced cost management or operational efficiency, surpassing market expectations.

European Commission approves Incyte’s Povofortay for hidradenitis suppurativa By Investing.com

https://ca.investing.com/news/stock-market-news/european-commission-approves-incytes-povofortay-for-hidradenitis-suppurativa-93CH-4962171
The European Commission has approved Incyte's Povofortay (povorcitinib) for the treatment of moderate to severe hidradenitis suppurativa in adults who have not responded adequately to or are intolerant to anti-tumor necrosis factor therapy. This approval is based on positive results from two Phase 3 trials, STOP-HS1 and STOP-HS2, demonstrating significant reductions in abscess and inflammatory nodule counts. Povofortay, an oral JAK1 selective inhibitor, is the first and only once-daily oral treatment approved in the EU for this condition, with a U.S. FDA review pending and anticipated launch in Q1 2027.

Incyte wins EU approval for povorcitinib to treat skin condition

https://www.streetinsider.com/Corporate+News/Incyte+wins+EU+approval+for+povorcitinib+to+treat+skin+condition/27355667.html
Incyte announced that the European Commission has approved Povofortay (povorcitinib) for the treatment of adults with moderate to severe hidradenitis suppurativa (HS). This marks the first once-daily oral treatment approved in the EU for this condition, based on successful Phase 3 trials. The drug is currently under review by the U.S. FDA, with anticipated approval and launch in early 2027.

An Incyte (INCY) officer proposes selling 2,642 shares acquired through an option exercise.

https://www.stocktitan.net/sec-filings/INCY/144-incyte-corp-sec-filing-d1bd70072062.html
Incyte Corporation (INCY) officer Pablo Cagnoni has proposed selling 2,642 common shares, valued at approximately $319,588.36, which were acquired through a stock option exercise on November 16, 2026. This proposed sale, with an approximate date of November 16, 2026, follows previous sales by Cagnoni in August, September, and October 2026, and is being executed under Rule 10b5-1. The notice details the transaction and affirms that the officer is not aware of any material adverse non-public information.
Advertisement

Europe approves the first once-daily pill for eligible adults with a chronic, painful skin disease.

https://www.stocktitan.net/news/INCY/povofortay-povorcitinib-approved-in-europe-as-the-first-once-daily-wtpdd3wpecar.html
The European Commission has approved Incyte's Povofortay (povorcitinib) as the first once-daily oral treatment for eligible adults with moderate to severe hidradenitis suppurativa (HS). This approval is based on Phase 3 STOP-HS1 and STOP-HS2 trials, which demonstrated the drug's efficacy and tolerability over 54 weeks. The U.S. Food and Drug Administration is also reviewing povorcitinib, with a potential approval and launch in the first quarter of 2027.

Weekly Recap: $6B 2029 revenue target and CFO projects $3B+ in 2026

https://www.tradingview.com/news/tradingview:61b8211f10220:0-weekly-recap-6b-2029-revenue-target-and-cfo-projects-3b-in-2026/
Natera, Inc. (NASDAQ:NTRA) is targeting $6 billion in revenue by 2029, with CFO Mike Brophy projecting over $3 billion in 2026. The company's growth is expected to be driven by its Signatera test, which recently entered a Phase II colorectal cancer trial partnership with Incyte. Despite a lowered price target from Baird, Natera's leadership defended a recent CEO transition, emphasizing team continuity.

Incyte Corp Lobbying Profile, 2023

https://www.opensecrets.org/federal-lobbying/clients/incyte-corp?client_id=192855&cycle=2023
This OpenSecrets profile details Incyte Corp's lobbying activities for 2023. As a client in the Pharmaceuticals/Health Products industry, Incyte Corp spent $1.61 million in direct federal lobbying as of July 23, 2026, for the 2026 period. The page provides a summary of their lobbying efforts, including hired firms, lobbyists, issues addressed, agencies targeted, and relevant bills.

Form 144 INCYTE CORPORATION For: 14 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-incyte-corporation-for-14-november-93CH-4958482
This article from Investing.com announces the filing of Form 144 for INCYTE CORPORATION on November 14. Form 144 is a notice of the intent to sell restricted securities. The article provides minimal detail beyond this notification.

Incyte cancels planned Phase 3 ovarian cancer study for CDK2 inhibitor

https://www.investing.com/news/sec-filings/incyte-cancels-planned-phase-3-ovarian-cancer-study-for-cdk2-inhibitor-93CH-5026755
Incyte Corporation has decided to cancel its planned Phase 3 MAESTRA-3 clinical study for its CDK2 inhibitor, INCB123667, in ovarian cancer treatment. This decision is part of the company's clinical development portfolio prioritization and is not based on any safety or efficacy concerns. Incyte does not expect this to impact its financial guidance, as the company maintains a strong balance sheet and is considered undervalued by InvestingPro analysis.
Advertisement

Incyte won't move ahead with phase 3 trial of ovarian cancer asset

https://www.tradingview.com/news/seekingalpha:353174be7094b:0-incyte-won-t-move-ahead-with-phase-3-trial-of-ovarian-cancer-asset/
Incyte Corp. has halted the planned phase 3 MAESTRA-3 trial for INCB123667 in combination with Avastin for first-line maintenance therapy in ovarian cancer. The decision is based on a prioritization of its clinical development portfolio and not on safety or efficacy findings. Incyte states this will not impact its financial guidance or long-term outlook.

Lee Heeson proposes selling 10,694 Incyte (INCY) shares acquired through stock award vesting.

https://www.stocktitan.net/sec-filings/INCY/144-incyte-corp-sec-filing-fb25c000a431.html
Lee Heeson, an officer at Incyte Corp. (INCY), has filed a Form 144 notice proposing to sell 10,694 common shares, valued at approximately $1,301,459.80. These shares were acquired through restricted stock unit vesting between October 1, 2025, and October 1, 2026, with an approximate sale date of November 13, 2026. This transaction is governed by a Rule 10b5-1 plan adopted on August 14, 2026.

Over 10 million Incyte (INCY) shares are held by one investment manager.

https://www.stocktitan.net/sec-filings/INCY/schedule-13g-a-incyte-corp-amended-passive-investment-disclosure-644aaf6d66d4.html
Dodge & Cox reported an amended ownership stake in Incyte Corp. (INCY), beneficially owning 10,064,186 shares of common stock, representing 5.0% of the class as of September 30, 2026. The investment manager holds sole voting power over 9,582,234 shares and sole dispositive power over all 10,064,186 shares. This filing provides transparency on institutional holdings and control over the company's stock.

Revenue falls 65% as MacroGenics (MGNX) swings from profit to a quarterly loss.

https://www.stocktitan.net/sec-filings/MGNX/10-q-macrogenics-inc-quarterly-earnings-report-18aba938f96f.html
MacroGenics (MGNX) reported a significant financial shift in Q3 2026, posting a $20.1 million net loss compared to a $16.8 million net income in the prior year, with total revenue decreasing by 65% to $18.7 million. This downturn is largely attributed to the completed sale of its CDMO operations, although the company recognized an $87.5 million net gain from the sale and aims to focus resources on its preclinical and clinical-stage pipeline. Despite the loss, the company's nine-month royalty revenue increased substantially due to higher ZYNYZ sales, and management believes current resources, partner payments, and cost savings will support operations through 2028.

Greater Philadelphia Life Sciences News: INOVIO's $75M Offering, Waters' MOBILion Acquisition & More

https://biobuzz.io/news/greater-philadelphia-life-sciences-news-inovio-s-75m-offering-waters-mobilion-acquisition/
The Greater Philadelphia life sciences ecosystem is experiencing significant activity, with companies raising capital, acquiring capabilities, and building talent pipelines. Notable events include INOVIO Pharmaceuticals pricing a $75 million public offering, Waters Corporation acquiring MOBILion Systems, and Charles River Laboratories expanding its preclinical drug development platform through an acquisition from Frontage. Additionally, the region is seeing leadership appointments and new healthcare training initiatives.
Advertisement

Wilmington’s Incyte Partners With Natera on Phase 2 Colorectal Cancer Trial Guided by MRD Testing

https://biobuzz.io/news/natera-announces-clinical-collaboration-with-incyte-on-interventional-phase-ii-study-in/
Incyte, a Wilmington, Delaware-based biopharmaceutical company, is partnering with Natera to use its Signatera™ blood test for a new Phase 2 colorectal cancer (CRC) trial. The trial will evaluate Incyte’s investigational immunotherapy, INCA33890, in patients with molecular residual disease (MRD) after surgery and chemotherapy. This collaboration aims to identify and treat patients whose cancer shows early signs of recurrence before it becomes visible on scans.

Incyte Corp. stock underperforms Wednesday when compared to competitors despite daily gains

https://www.marketwatch.com/data-news/incyte-corp-stock-underperforms-wednesday-when-compared-to-competitors-despite-daily-gains-8c4684a4-3f36be0bfd95?mod=goog_fin_scmw
Incyte Corp. (INCY) stock increased by 1.64% on Wednesday to $122.27, despite underperforming compared to its competitors. The broader market also saw gains, with the S&P 500 Index rising 1.31% and the Dow Jones Industrial Average rising 0.49%. The company's stock closed 7.79% below its 52-week high of $132.60.

Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer

https://www.biospace.com/press-releases/natera-announces-clinical-collaboration-with-incyte-on-interventional-phase-ii-study-in-colorectal-cancer
Natera has announced a clinical collaboration with Incyte for a new Phase II study in colorectal cancer (CRC). The trial will evaluate Incyte's investigational bispecific immunotherapy, INCA33890, in patients with stage 2/3 CRC who are MRD-positive after surgery and adjuvant chemotherapy, using Natera's Signatera test as a key endpoint. This collaboration aims to identify high-risk patients for targeted treatment and improve outcomes by leveraging Natera's expertise in MRD-guided clinical trial design.

Natera, Incyte partner on colorectal cancer trial using MRD test

https://www.investing.com/news/company-news/natera-incyte-partner-on-colorectal-cancer-trial-using-mrd-test-93CH-5015021
Natera Inc. and Incyte have announced a clinical collaboration for a Phase II study evaluating Incyte’s investigational bispecific immunotherapy, INCA33890, in patients with stage 2/3 colorectal cancer. Natera's Signatera test will serve as both a primary and secondary endpoint, identifying patients who are MRD-positive after surgery and adjuvant chemotherapy for potential enrollment. This partnership aims to address the significant unmet need in patients with elevated recurrence risk.

Natera and Incyte team up on phase II colorectal cancer trial

https://www.streetinsider.com/Corporate+News/Natera+and+Incyte+team+up+on+phase+II+colorectal+cancer+trial/27318377.html
Natera and Incyte have announced a clinical collaboration for a Phase II study in colorectal cancer. The trial will evaluate Incyte's investigational bispecific immunotherapy, INCA33890, in patients with stage 2 or 3 colorectal cancer, using Natera's Signatera test as both a primary and secondary endpoint to identify eligible patients who remain MRD-positive after surgery and chemotherapy. This partnership aims to address the unmet need in this patient population which faces a significantly elevated risk of recurrence.
Advertisement

Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer

https://www.stocktitan.net/news/INCY/natera-announces-clinical-collaboration-with-incyte-on-9rxquz6nyurn.html
Natera has announced a clinical collaboration with Incyte for a new Phase II study in colorectal cancer (CRC), which will evaluate Incyte’s investigational bispecific immunotherapy, INCA33890. The study will use Natera's Signatera test to identify high-risk patients with stage 2/3 CRC who are MRD-positive after surgery and adjuvant chemotherapy, aiming to improve outcomes through Signatera-guided treatment. Natera will also provide trial matching services, leveraging its expertise in MRD-guided trial strategy and design.

Is Neurocrine Biosciences (NBIX) Still Cheap As INGREZZA Data And Earnings Outlook Lift Sentiment?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbix/neurocrine-biosciences/news/is-neurocrine-biosciences-nbix-still-cheap-as-ingrezza-data
Neurocrine Biosciences (NBIX) has seen positive momentum with a 16.17% 7-day share price return and an 18.55% 30-day return, driven by fresh INGREZZA patient outcome data and a strengthened earnings outlook. Despite recent gains, Simply Wall St's analyst consensus views the stock as 18% undervalued, with a fair value of $206.81 per share compared to its last close of $168.86. However, potential risks include tougher INGREZZA pricing and reimbursement challenges, as well as VYKAT XR safety or uptake setbacks.

Natera, Incyte Collaborate on Interventional Phase II Study in Colorectal Cancer

https://www.genomeweb.com/diagnostics/molecular/liquid-biopsy/ctdna/gnw-natera-incyte-collaboration-colorectal-cancer-20261110/
Natera and Incyte have announced a collaboration on an interventional Phase II study focusing on colorectal cancer. The details of the study, including its design and specific objectives, were not fully provided in the snippet, but it signifies a joint effort in advancing cancer diagnostics and treatment.

Incyte Raises Sales Outlook as Drug Revenue Climbs 14%

https://www.mychesco.com/a/news/regional/incyte-raises-sales-outlook-as-drug-revenue-climbs-14/
Incyte Corp. increased its full-year 2026 sales forecast after reporting a 14% rise in third-quarter revenue to $1.56 billion, driven by growth in its dermatology and oncology businesses, which is reducing its reliance on its flagship blood cancer treatment, Jakafi. The company raised its full-year product sales guidance to between $5.21 billion and $5.30 billion, reflecting strong demand for its marketed treatments, despite a significant increase in research and development expenses due to its acquisition of Vega Therapeutics. Incyte is also advancing several late-stage development programs across blood disorders, gastrointestinal cancers, and inflammatory diseases.

The Strong Earnings Posted By Neurocrine Biosciences (NASDAQ:NBIX) Are A Good Indication Of The Strength Of The Business

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbix/neurocrine-biosciences/news/the-strong-earnings-posted-by-neurocrine-biosciences-nasdaqn
Neurocrine Biosciences recently reported strong earnings, which were positively received by the market. Further analysis reveals encouraging factors for investors, such as a negative accrual ratio of -0.13, indicating strong cash conversion with free cash flow significantly exceeding statutory profit. The company's profit was also impacted by unusual items worth US$122m, which contributed to high cash conversion, suggesting that underlying earnings power may be better than statutory numbers appear.
Advertisement

Raised Sales Guidance Could Be A Big Test For Incyte Stock (INCY)

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-incy/incyte/news/raised-sales-guidance-could-be-a-big-test-for-incyte-stock-i
Incyte reported Q3 2026 revenue of US$1,557.2 million and a net loss of US$784.8 million, while increasing its full-year 2026 net sales guidance to US$5,210 million to US$5,300 million. Despite significant development spending and a lower year-to-date net income, new Phase 1 oncology data shows promise. The raised guidance, alongside ongoing R&D intensity, sets a higher bar for execution on upcoming launches and label expansions, with risks tied to whether heavy spending translates into broader revenue beyond Jakafi.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/agios-pharmaceuticals-inc-nasdaqagio-third-quarter-results-j
Agios Pharmaceuticals (NASDAQ:AGIO) exceeded analyst expectations in its third-quarter results, with revenues of US$55m, beating estimates by 7.3%. Analysts are forecasting revenues of US$347.4m in 2027, a 147% improvement, and expect losses per share to narrow by 40% to US$3.75. The consensus price target remains at US$45.88, indicating the business is trading in line with expectations despite ongoing losses.

Incyte Advances Pancreatic and Colorectal Cancer Drug Trials

https://www.mychesco.com/a/news/regional/incyte-advances-pancreatic-and-colorectal-cancer-drug-trials/
Incyte Corp. is progressing two experimental cancer treatments, INCB161734 and INCA33890, into late-stage clinical trials for pancreatic and colorectal cancers. Early-stage results presented at the 2026 ESMO Congress showed encouraging tumor responses and manageable safety profiles, supporting ongoing and planned Phase 3 studies. The company is also collaborating on new combination therapies to improve outcomes for patients with these difficult-to-treat solid tumors.

Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Novavax (NVAX)

https://www.theglobeandmail.com/investing/markets/stocks/NVAX/pressreleases/8716438/analysts-offer-insights-on-healthcare-companies-incyte-incy-and-novavax-nvax/
Analysts have provided new ratings on Incyte (INCY) and Novavax (NVAX) in the Healthcare sector. H.C. Wainwright maintained a Buy rating on Incyte with a $152.00 price target, while Bank of America Securities reiterated a Sell rating on Novavax with a $7.00 price target. The article details analyst consensus and price targets for both companies.

Form 144 INCYTE CORPORATION For: 7 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-incyte-corporation-for-7-november-93CH-4940893
This article announces the filing of Form 144 for Incyte Corporation (INCY) on November 7, 2026. Form 144 is a notice of the intent to sell restricted securities. The article provides the title and date of the filing, along with market data for various indices, commodities, and stocks.
Advertisement

Incyte Corporation (INCY) Seasonal Returns Chart

https://ca.finance.yahoo.com/quote/INCY/seasonality/
This article provides a seasonal returns chart for Incyte Corporation (INCY), detailing the average monthly price return from 2016 to 2026. The information includes real-time stock data and historical seasonality for various timeframes.

No-Moat Incyte's Pipeline Momentum Strengthens Long-Term Growth Prospects

https://www.morningstar.com/company-reports/1508955-no-moat-incytes-pipeline-momentum-strengthens-long-term-growth-prospects
Morningstar believes Incyte's pipeline momentum, particularly with Opzelura and new combination therapies in hematology, is strengthening its long-term growth prospects. While the company built a strong foundation with Jakafi, key data is awaited to confirm significant growth beyond Jakafi's patent expiration in 2028.

Inventiva among the biggest decliners in the SBF 120, down 4%

https://www.ideal-investisseur.fr/en/stock-news/inventiva-among-the-biggest-decliners-in-the-sbf-120-down-4/28885.html
Inventiva, a biotech company specializing in fibrotic and metabolic diseases, saw its shares decline by 4.17% in the SBF 120 index. This drop placed it among the biggest decliners, erasing part of its recent rebound, and occurred amidst a broader market downturn influenced by Wall Street's performance. The company's financial outlook also notes a limited cash runway to Q2 2027 without additional financing, despite recent funding efforts.

Incyte Corp principal accounting officer sells $72,565 of stock

https://www.investing.com/news/insider-trading-news/incyte-corp-principal-accounting-officer-sells-72565-of-stock-93CH-5006564
Tray Thomas, Principal Accounting Officer at Incyte Corp, sold 610 shares of company stock for $72,565 on November 3, 2026. Despite the sale occurring near current trading levels, InvestingPro analysis indicates the stock is undervalued with a Fair Value of $147.12. The company recently reported strong Q3 2026 revenue of $1.56 billion, exceeding forecasts, and has received analyst upgrades citing a positive growth outlook.

Form 4 Incyte Corporation: Thomas Tray (Principal Accounting Officer) For: 3 November

https://ca.investing.com/news/stock-market-news/form-4-incyte-corporation-thomas-tray-principal-accounting-officer-for-3-november-93CH-4937495
This article reports on a Form 4 filing for Incyte Corporation, specifically detailing insider transactions by Thomas Tray, the Principal Accounting Officer. The filing is in relation to activity on November 3. The information is provided by Investing.com.
Advertisement

Halozyme Q3 2026: Record Royalties Drive a Guidance Raise

https://247wallst.com/cards/halozyme-therapeutics-q3-2026-earnings-halo-01m6prps2mjnj2wsmdj9kwnv8s
Halozyme Therapeutics reported strong Q3 2026 results, with non-GAAP EPS of $2.39 and revenue up 39.1% year over year, driven by record ENHANZE royalty income of $341 million. This led management to raise its full-year 2026 guidance for revenue, royalty revenue, and non-GAAP diluted EPS, highlighting the company's shift towards high-margin royalty streams. Despite the positive report, shares experienced a slight dip immediately after the release.

Halozyme falls 6% as raised guidance fails to impress investors By Investing.com

https://www.investing.com/news/earnings/halozyme-falls-6-as-raised-guidance-fails-to-impress-investors-5006041
Halozyme Therapeutics Inc. shares dropped 6% in after-hours trading despite reporting strong third-quarter results that surpassed Wall Street expectations. The biotechnology company raised its full-year 2026 guidance for revenue, adjusted EPS, and adjusted EBITDA, but the updated outlook still fell short of elevated investor expectations. Royalty revenue, a key driver, saw a 44% year-over-year increase, and the company achieved a legal victory regarding patent infringement.

Halozyme Therapeutics Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62958934/halozyme-therapeutics-q3-2026-earnings-call-transcript
Halozyme Therapeutics reported strong Q3 2026 financial results with a 39% increase in total revenue to $493 million and a 44% rise in royalty revenue to $341 million, driven by the continued growth of ENHANZE-enabled products like Darzalex Subcutaneous and Vyvgart Hytrulo. The company expanded its ENHANZE opportunity with new target nominations and advanced multiple programs into clinical development, raising its full-year 2026 revenue guidance. Halozyme also secured significant legal victories in Europe against Merck regarding its Keytruda subcutaneous patent, preventing its launch in key markets, and is progressing its HyperCon and AeroCon hyperconcentration technologies towards clinical trials in 2027 and 2028, respectively.

Halozyme Therapeutics (NASDAQ:HALO) surprises with Q3 2026 sales but stock drops

https://uk.finance.yahoo.com/news/halozyme-therapeutics-nasdaq-halo-surprises-211024585.html
Halozyme Therapeutics (NASDAQ:HALO) reported better-than-expected Q3 2026 revenue of $493 million, up 39.2% year-on-year, and raised its full-year revenue and EBITDA guidance. Despite these positive financial results and strong long-term revenue growth, the company's stock dropped by 5.6% immediately after the announcement. The decline was attributed to the market potentially hoping for even stronger results, despite the solid performance.

Halozyme falls 6% as raised guidance fails to impress investors

https://finance.yahoo.com/healthcare/articles/halozyme-falls-6-raised-guidance-232957265.html
Halozyme Therapeutics Inc. (NASDAQ:HALO) reported better-than-expected third-quarter results, with adjusted EPS of $2.39 and revenue climbing 39% YoY to $493 million. However, shares fell 6% in after-hours trading as the company's raised full-year 2026 guidance, while slightly above consensus, failed to meet elevated investor expectations. The company also announced expanded ENHANZE collaboration agreements, progress in clinical development, and a legal victory against Merck.
Advertisement

Incyte Corp. stock underperforms Thursday when compared to competitors

https://www.marketwatch.com/data-news/incyte-corp-stock-underperforms-thursday-when-compared-to-competitors-923071fc-23421f770bc6
Incyte Corp. (INCY) shares fell 3.94% to $118.01 on Thursday, underperforming the broader market which also saw declines with the S&P 500 Index and Dow Jones Industrial Average falling significantly. The stock closed 11.00% below its 52-week high of $132.60 reached in July.

Halozyme Therapeutics (NASDAQ:HALO) surprises with Q3 2026 sales but stock drops

https://markets.financialcontent.com/stocks/article/stockstory-2026-11-5-halozyme-therapeutics-nasdaqhalo-surprises-with-q3-2026-sales-but-stock-drops
Halozyme Therapeutics reported better-than-expected Q3 2026 revenue of $493 million, a 39.2% year-on-year increase, and raised its full-year revenue and adjusted EPS guidance. Despite strong financial performance and expanded agreements, the company's stock dropped 5.6% immediately after the results were announced. The article details the company's financial highlights, revenue and EPS growth, and adjusted operating margins.

Is Incyte (INCY) Undervalued On Trial Progress And Raised Sales Guidance?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-incy/incyte/news/is-incyte-incy-undervalued-on-trial-progress-and-raised-sale
Incyte (INCY) has seen its share price increase by 4.47% on recent news, contributing to a 21.13% year-to-date return, following positive trial data for oncology therapies and raised full-year sales guidance for 2026. Despite this rally, the company is considered 6% undervalued with a fair value of $131.08, slightly above its current $122.85 close. However, its P/E ratio of 62.1x is significantly higher than the industry average, suggesting investors are taking on valuation risk.

Xencor Reports Third Quarter 2026 Financial Results

https://www.biospace.com/press-releases/xencor-reports-third-quarter-2026-financial-results
Xencor, Inc. reported its financial results for the third quarter ended September 30, 2026, highlighting progress across its clinical-stage pipeline for cancer and autoimmune diseases. Key updates include compelling clinical data for XmAb819 in advanced clear cell renal cell carcinoma, upcoming presentations for plamotamab in rheumatoid arthritis, and on-track development for TL1A-targeting programs XmAb942 and XmAb412. The company also detailed significant milestones achieved with partners Amgen, Astellas, and Zenas BioPharma, and reported a net income of $39.4 million for the quarter.

What Precigen (PGEN) Said on Its Q3 Earnings Call

https://www.tradingview.com/news/marketbeat:ff76aa831094b:0-what-precigen-pgen-said-on-its-q3-earnings-call/
Precigen (PGEN) reported strong Q3 2026 results, with PAPZIMEOS sales reaching $72.9 million, contributing to a second consecutive profitable quarter and positive cash flow. The company is preparing for competition in the recurrent respiratory papillomatosis (RRP) market, confident in PAPZIMEOS's commercial advantage, clinical results, and established reimbursement. Precigen also outlined plans for redosing studies, pediatric development, international expansion, and further development of its AdenoVerse platform.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement